Table 1.
Factor | mRS ≤ 2 | mRS > 2 | P-value |
---|---|---|---|
Number of cases | 74 | 34 | |
Gender | 0.679 | ||
1 | 38 (51%) | 16 (47%) | |
2 | 36 (49%) | 18 (53%) | |
Age | 0.127 | ||
<15 | 17 (23%) | 3 (9%) | |
15–24 | 28 (38%) | 10 (29%) | |
25–34 | 22 (30%) | 15 (44%) | |
35–45 | 7 (9%) | 6 (18%) | |
Memory dysfunction | 0.241 | ||
0 | 52 (70%) | 20 (59%) | |
1 | 22 (30%) | 14 (41%) | |
Speech disorders | 0.24 | ||
0 | 54 (73%) | 21 (62%) | |
1 | 20 (27%) | 13 (38%) | |
Behavioral changes | 0.123 | ||
0 | 31 (42%) | 9 (26%) | |
1 | 43 (58%) | 25 (74%) | |
Seizures | 0.458 | ||
0 | 25 (34%) | 14 (41%) | |
1 | 49 (66%) | 20 (59%) | |
Consciousness disorder | 0.003 | ||
0 | 63 (85%) | 20 (59%) | |
1 | 11 (15%) | 14 (41%) | |
Sleep dysfunction | 0.579 | ||
0 | 62 (84%) | 27 (79%) | |
1 | 12 (16%) | 7 (21%) | |
Movement disorder | 0.016 | ||
0 | 58 (78%) | 19 (56%) | |
1 | 16 (22%) | 15 (44%) | |
Autonomic dysfunction | 0.131 | ||
0 | 71 (96%) | 30 (88%) | |
1 | 3 (4%) | 4 (12%) | |
Viral prodrome | 0.145 | ||
0 | 35 (47%) | 11 (32%) | |
1 | 39 (53%) | 23 (68%) | |
CSF WBC count (>20 cell/μL) | 0.105 | ||
0 | 45 (61%) | 15 (44%) | |
1 | 29 (39%) | 19 (56%) | |
CSF protein (>30 mg/dL) | 0.914 | ||
0 | 34 (46%) | 16 (47%) | |
1 | 40 (54%) | 18 (53%) | |
Abnormal MRI | 0.761 | ||
0 | 28 (38%) | 12 (35%) | |
1 | 45 (62%) | 22 (65%) | |
Tumor | 0.571 | ||
0 | 70 (95%) | 33 (97%) | |
1 | 4 (5%) | 1 (3%) | |
Immunotherapy latency (>4 wk) | 0.077 | ||
0 | 44 (59%) | 14 (41%) | |
1 | 30 (41%) | 20 (59%) |
Data presented as n (%).
mRS, modified Rankin Scale; anti-NMDARE, anti-N-methyl-D-aspartate receptor encephalitis; CSF, cerebrospinal fluid; WBC, white blood cell; MRI, magnetic resonance imaging.
Univariate binary logistic regression analysis was conducted using the Fisher exact test; the P-value was derived from bivariate association analyses between each study variables and the mRS score.